IMAC - IMAC completes first infusion of stem cells in parkinson's disease study

IMAC Holdings ([[IMAC]] +14.7%) announces completion of the first infusion of its investigational compound utilizing stem cells in its Phase 1 clinical trial for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinson’s disease."We anticipate full patient enrollment by the end of February 2021, with subsequent infusions continuing in early 2021,” CEO Jeffrey Ervin said.The trial will be divided into three groups. Five patients with bradykinesia due to Parkinson’s disease will receive a low dose, intravenous infusion of stem cells, five patients will receive a medium intravenous dose, and another five patients will receive a high intravenous dose.“We have already received significant interest from patients across our regenerative medicine centers to participate in the trial, and we are actively screening these inquiries to identify those who fit the inclusion criteria of the trial," he added.IMAC shares have lost nearly 20% of their value this

For further details see:

IMAC completes first infusion of stem cells in parkinson’s disease study